Possible contribution of cytomegalovirus infection to the high risk of (recurrent) venous thrombosis after renal transplantation

Thrombosis and Haemostasis

Volumn 99, Issue 1, 2008, Pages 127-130

  Lijfering, Willem M ^a   de Vries, Aiko P J ^a   Veeger, Nic J G M ^a   van Son, Willem J ^a   Bakker, Stephan J L ^a   van der Meer, Jan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cytomegalovirus; Recurrent venous thrombosis; Renal transplant recipients; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADOLESCENT; ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; FEMALE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; THROMBECTOMY; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOUS THROMBOSIS;

EID: 38349130427     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-05-0340     Document Type: Article

References (30)

1. Humar A, Johnson EM, Gillingham KJ, et al. Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis. Transplantation 1998; 65: 229-234.
2. Poli D, Zanazzi M, Antonucci E, et al. Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. J Thromb Haemost 2006; 4: 988-992.
3. Poli D, Zanazzi M, Antonucci E, et al. High rate of recurrence in renal transplant recipients after a first episode of venous thromboembolism. Transplantation 2005; 80: 789-793.
4. Patrassi GM, Sartori MT, Rigotti P, et al. Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. Transplantation 1995; 59: 1416-1420.
5. Ducloux D, Pellet E, Fournier V, et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67: 90-93.
6. Kazory A, Ducloux D, Coaquette A, et al. Cytomegalovirus-associated venous thromboembolism in renal transplant recipients: a report of 7 cases. Transplantation 2004; 77: 597-599.
7. Rowshani AT, Bemelman FJ, van Leeuwen EM, et al. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005; 79: 381-386.
8. Span AH, van Dam-Mieras MC, Mullers W, et al. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells. Eur J Clin Invest 1991; 21: 331-338.
9. Grefte A, van der Giessen M, van Son W, et al. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis 1993; 167: 270-277.
10. Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31: 256-263.
11. Schambeck CM, Hinney K, Gleixner J, et al. Venous thromboembolism and associated high plasma factor VIII levels: linked to cytomegalovirus infection? Thromb Haemost. 2000; 83: 510-511.
12. The TH, Kas-Deelen AM, de Maar EF, et al. Cellular and humoral parameters for vascular damage in blood during cytomegalovirus infections. Transplant Proc 2001; 33: 1813.
13. Lebranchu Y, al Najjar A, Kapahi P, et al. The association of increased soluble VCAM-1 levels with CMV disease in human kidney allograft recipients. Transplant Proc 1995; 27: 960.
14. Gonzalez-Ordonez AJ, Fernandez-Carreira JM, Fernandez-Alvarez CR, et al. The concentrations of soluble vascular cell adhesion molecule-1 and lipids are independently associated with venous thromboembolism. Haematologica 2003; 88: 1035-1043.
15. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 3: 79-84.
16. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
17. Abgueguen P, Delbos V, Chennebault JM, et al. Vascular thrombosis and acute cytomegalovirus infection in immunocompetent patients: report of 2 cases and literature review. Clin Infect Dis 2003; 36: E134-139.
18. Squizzato A, Gerdes VE, Buller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005; 93: 403-410.
19. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc 1989; 261: 3561-3566.
20. Van der Giessen M, van den Berg AP, van der Bij W, et al. Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection. Clin Exp Immunol 1990; 80: 56-61.
21. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
22. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158: 1525-1531.
23. Abbott KC, Cruess DF, Agodoa LY, et al. Early renal insufficiency and late venous thromboembolism after renal transplantation in the United States. Am J Kidney Dis. 2004; 43: 120-130.
24. Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation 2001; 71: SS5-9.
25. Kas-Deelen AM, Harmsen MC, De Maar EF, et al. Acute rejection before cytomegalovirus infection enhances von Willebrand factor and soluble VCAM-1 in blood. Kidney Int 2000; 58: 2533-2542.
26. Gouarin S, Vabret A, Gault E, et al. Quantitative analysis of HCMV DNA load in whole blood of renal transplant patients using real-time PCR assay. J Clin Virol 2004; 29: 194-201.
27. Heit A Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768.
28. van den Belt AG, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157: 2227-2232.
29. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
30. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-61.